Zynerba Pharmaceuticals Stock News

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported results for the first quarter that reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel (ZYN00

– Data support the long-term safety and effectiveness of Zygel –

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc, a leader in transdermal cannabinoid therapies for rare neuropsychiatric disorders, revealed that it is making an oral podium presentation at the Internationa

DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

DEVON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it presented a poster on the long-term safety and efficacy of its cannabidiol transdermal gel, Zygel, at the 2022 Society of Biological Psychiatry (SOBP)

DEVON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-ra

DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we mak

New York, March 02, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Marvel Discovery completes airborne magnetic survey on Gander East project click here Canaccord Genuity calls Zynerba "undervalued," reiterates ''Buy'' rating after positive 4Q results click here Infield Minerals plans to advance Desperado property with 2,000-meter reverse circulation drilling campaign click here Viscount Mining announces results from New Century-Rattlesnake target in Cherry Creek, Nevada click here Stifel GMP repeats ''Buy'' on Steppe Gold as it restarts heap leach processing to recover gold and silver at its ATO mine in Mongolia click here Kootenay Silver says JV partner Aztec Minerals hits "best hole yet" at Cervantes project in Mexico click here MedX Health strikes agreement with Health Partners to launch tele dermatology screening platform in the UK click here Healixa secures an additional $22.

Canaccord Genuity (TSX:CF, LSE:CF) said it continued to believe that Zynerba Pharmaceuticals (NASDAQ:ZYNE) is undervalued after the company reported its fourth-quarter financial results that showed a

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ) reported Tuesday f inancial results for the fourth quarter and full year ended December 31, 2021. “In 2022, we look to build on last year’s progress as we continue to enroll patients in our confirmatory pivotal Phase 3 trial in Fragile X syndrome, initiate a Phase 3 program in autism spectrum disorder and report topline results in our Phase 2 trial in 22q11.2 deletion syndrome,” Armando Anido , chairman and chief executive officer of Zynerba stated. “We are committed to achieving our goal of bringing the first pharmaceutical product indicated for the treatment of behavioral symptoms of Fragile X syndrome to market, as well as advancing Zygel in other rare and near rare neuropsychiatric indications.” Q4 And Full Year 2021 Financial Highlights Research and development expenses were $21.4 million for full year 2021, including stock-based compensation of $2.8 million.

Zynerba Pharmaceuticals press release (ZYNE): Q4 GAAP EPS of -$0.22 beats by $0.04.As of December 31, 2021, cash and cash equivalents were $67.8M, compared to $59.2M as of December…

– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) –